What Researchers Did
Researchers reviewed studies on non-surgical treatments for chronic rectal inflammation (proctitis) that can develop after pelvic radiotherapy for cancer.
What They Found
This Cochrane systematic review identified six randomized controlled trials evaluating non-surgical treatments for late radiation proctitis, with most comparisons based on a single small trial. Rectal sucralfate showed greater clinical improvement than anti-inflammatory treatment (odds ratio 14.00, 95% confidence interval 1.46 to 134.26, one study), though no difference was seen for endoscopic improvement (odds ratio 2.74, 95% confidence interval 0.64 to 11.76, one study). Adding metronidazole to an anti-inflammatory regimen appeared to improve response rates, measured by reduced bleeding, diarrhea, redness, and ulceration, in one study, and rectal hydrocortisone appeared more effective than rectal betamethasone for clinical improvement, though again no difference was seen endoscopically. Short chain fatty acid enemas did not appear effective compared to placebo across two studies, and in a comparison of heater probe versus bipolar electrocautery, there was no discernible difference in severe bleeding after one year, though the heater probe showed a greater increase in blood count and reduced transfusion needs.
What This Means for Canadian Patients
This abstract does not address hyperbaric oxygen therapy and cannot be used to draw conclusions about it. The reviewers describe several non-surgical treatments, including rectal sucralfate, added metronidazole, rectal hydrocortisone, and heater probe treatment, as promising, but state plainly that single small studies, even when well conducted, provide insufficient evidence to establish any of them as a recommended treatment.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
Most comparisons in this review rely on a single small trial rather than confirmed large-scale evidence, and the reviewers themselves call for placebo-controlled, multi-center trials with standardized outcome measures before any of these treatments can be considered established.